Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Manufacturing Amorphous Solid Dispersions with a Tailored Amount of Crystallized API for Biopharmaceutical Testing.

Theil F, Milsmann J, Anantharaman S, van Lishaut H.

Mol Pharm. 2018 May 7;15(5):1870-1877. doi: 10.1021/acs.molpharmaceut.8b00043. Epub 2018 Apr 12.

PMID:
29648833
2.

Extraordinary Long-Term-Stability in Kinetically Stabilized Amorphous Solid Dispersions of Fenofibrate.

Theil F, Milsmann J, Kyeremateng SO, Anantharaman S, Rosenberg J, van Lishaut H.

Mol Pharm. 2017 Dec 4;14(12):4636-4647. doi: 10.1021/acs.molpharmaceut.7b00735. Epub 2017 Nov 16.

PMID:
29111751
3.

Synthesis of M + 4 Stable Isotopomers of Ergometrine and Ergometrinine.

Braun B, Köppen R, Wedler C, Theil F.

Nat Prod Commun. 2017 Mar;12(3):373-6.

PMID:
30565445
4.

Frozen in Time: Kinetically Stabilized Amorphous Solid Dispersions of Nifedipine Stable after a Quarter Century of Storage.

Theil F, Anantharaman S, Kyeremateng SO, van Lishaut H, Dreis-Kühne SH, Rosenberg J, Mägerlein M, Woehrle GH.

Mol Pharm. 2017 Jan 3;14(1):183-192. doi: 10.1021/acs.molpharmaceut.6b00783. Epub 2016 Nov 30.

PMID:
28043131
5.

Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development.

Lu Y, Khawli LA, Purushothama S, Theil FP, Partridge MA.

J Immunol Res. 2016;2016:8141269. doi: 10.1155/2016/8141269. Epub 2016 Aug 23. No abstract available.

6.

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.

Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, Theil FP.

J Immunol Res. 2016;2016:2342187. doi: 10.1155/2016/2342187. Epub 2016 Aug 8. Review.

7.

Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.

Ferl GZ, Theil FP, Wong H.

Biopharm Drug Dispos. 2016 Mar;37(2):75-92. doi: 10.1002/bdd.1994. Review.

PMID:
26461173
8.

Insights into the mechanism of polymer coating self-healing using Raman spectroscopy.

Vasiliu S, Kampe B, Theil F, Dietzek B, Döhler D, Michael P, Binder WH, Popp J.

Appl Spectrosc. 2014;68(5):541-8. doi: 10.1366/13-07332.

PMID:
25014597
9.

New challenges and opportunities in nonclinical safety testing of biologics.

Baumann A, Flagella K, Forster R, de Haan L, Kronenberg S, Locher M, Richter WF, Theil FP, Todd M.

Regul Toxicol Pharmacol. 2014 Jul;69(2):226-33. doi: 10.1016/j.yrtph.2014.04.005. Epub 2014 Apr 19.

PMID:
24755365
10.

Ru dye functionalized Au-SiO2@TiO2 and Au/Pt-SiO2@TiO2 nanoassemblies for surface-plasmon-induced visible light photocatalysis.

Theil F, Dellith A, Dellith J, Undisz A, Csáki A, Fritzsche W, Popp J, Rettenmayr M, Dietzek B.

J Colloid Interface Sci. 2014 May 1;421:114-21. doi: 10.1016/j.jcis.2014.01.029. Epub 2014 Jan 31.

PMID:
24594039
11.

Current challenges and opportunities in nonclinical safety testing of biologics.

Kronenberg S, Baumann A, de Haan L, Hinton HJ, Moggs J, Theil FP, Wakefield I, Singer T.

Drug Discov Today. 2013 Dec;18(23-24):1138-43. doi: 10.1016/j.drudis.2013.08.003. Epub 2013 Aug 11.

PMID:
23942260
12.

An algorithm for evaluating potential tissue drug distribution in toxicology studies from readily available pharmacokinetic parameters.

Poulin P, Dambach DM, Hartley DH, Ford K, Theil FP, Harstad E, Halladay J, Choo E, Boggs J, Liederer BM, Dean B, Diaz D.

J Pharm Sci. 2013 Oct;102(10):3816-29. doi: 10.1002/jps.23670. Epub 2013 Jul 22.

PMID:
23878104
13.

A strategy for risk mitigation of antibodies with fast clearance.

Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, Fielder P, Carter PJ, Kelley RF.

MAbs. 2012 Nov-Dec;4(6):753-60. doi: 10.4161/mabs.22189.

14.

Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states.

Deo AK, Theil FP, Nicolas JM.

Mol Pharm. 2013 May 6;10(5):1581-95. doi: 10.1021/mp300570z. Epub 2013 Jan 4. Review.

PMID:
23256608
15.

Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology.

Prabhu S, Boswell CA, Leipold D, Khawli LA, Li D, Lu D, Theil FP, Joshi A, Lum BL.

Ther Deliv. 2011 Jun;2(6):769-91. Review.

PMID:
22822508
16.

Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans.

Xin Y, Bai S, Damico-Beyer LA, Jin D, Liang WC, Wu Y, Theil FP, Joshi A, Lu Y, Lowe J, Maia M, Brachmann RK, Xiang H.

Pharm Res. 2012 Sep;29(9):2512-21. doi: 10.1007/s11095-012-0781-x. Epub 2012 Jun 16.

PMID:
22707361
17.

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.

Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil FP, Tibbitts J, Friedman LS, Hop CE, Gould SE.

Clin Cancer Res. 2012 Jul 15;18(14):3846-55. doi: 10.1158/1078-0432.CCR-12-0738. Epub 2012 May 30.

18.

Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW.

World J Biol Chem. 2012 Apr 26;3(4):73-92. doi: 10.4331/wjbc.v3.i4.73.

19.

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.

Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, Grimm HP, Joshi A, Justies N, Kolaitis G, Lewin-Koh N, Li J, McVay S, O'Mahony J, Otteneder M, Pantze M, Putnam WS, Qiu ZJ, Ruppel J, Singer T, Stauch O, Theil FP, Visich J, Yang J, Ying Y, Khawli LA, Richter WF.

MAbs. 2012 Mar-Apr;4(2):243-55. doi: 10.4161/mabs.4.2.19387. Epub 2012 Mar 1.

20.

Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.

Xin Y, Xiang H, Jin D, Theil FP, Joshi A, Damico-Beyer LA, Bai S.

J Pharmacokinet Pharmacodyn. 2012 Apr;39(2):217-26. doi: 10.1007/s10928-012-9244-6. Epub 2012 Mar 1.

PMID:
22382554
21.

Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.

Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, Prabhu S.

MAbs. 2012 Jan-Feb;4(1):101-9. doi: 10.4161/mabs.4.1.18543.

22.

Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.

Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA.

Mol Cancer Ther. 2012 Mar;11(3):752-62. doi: 10.1158/1535-7163.MCT-11-0742-T. Epub 2012 Jan 5.

23.

Surface-enhanced Raman spectroscopy (SERS): progress and trends.

Cialla D, März A, Böhme R, Theil F, Weber K, Schmitt M, Popp J.

Anal Bioanal Chem. 2012 Apr;403(1):27-54. doi: 10.1007/s00216-011-5631-x. Epub 2011 Dec 29.

PMID:
22205182
24.

Highlights from a recent BIO survey on therapeutic protein-drug interactions.

Pharmacokinetics and Disposition Expert Working Group Drug-Drug Interaction Taskforce, Lloyd P, Zhou H, Theil FP, Kakkar T, Nestorov I, Roberts SA.

J Clin Pharmacol. 2012 Nov;52(11):1755-63. doi: 10.1177/0091270011424144. Epub 2011 Dec 13. No abstract available.

PMID:
22167564
25.

Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Bumbaca D, Xiang H, Boswell CA, Port RE, Stainton SL, Mundo EE, Ulufatu S, Bagri A, Theil FP, Fielder PJ, Khawli LA, Shen BQ.

Br J Pharmacol. 2012 May;166(1):368-77. doi: 10.1111/j.1476-5381.2011.01777.x.

26.

Influence of the compound selection process on the performance of human clearance prediction methods.

Wong H, Lewin-Koh SC, Theil FP, Hop CE.

J Pharm Sci. 2012 Feb;101(2):509-15. doi: 10.1002/jps.22786. Epub 2011 Oct 4.

PMID:
21976152
27.

Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.

Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, Gill H, Shen BQ, Rubinfeld B, Tibbitts J, Kaur S, Theil FP, Fielder PJ, Khawli LA, Lin K.

Bioconjug Chem. 2011 Oct 19;22(10):1994-2004. doi: 10.1021/bc200212a. Epub 2011 Oct 3.

PMID:
21913715
28.

Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components.

Richter WF, Grimm HP, Theil FP.

J Pharmacokinet Pharmacodyn. 2011 Oct;38(5):581-93. doi: 10.1007/s10928-011-9209-1. Epub 2011 Jul 21.

PMID:
21779940
29.

Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow.

Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, Fielder PJ, Khawli LA.

PLoS One. 2011 Mar 15;6(3):e17874. doi: 10.1371/journal.pone.0017874.

30.

Effects of charge on antibody tissue distribution and pharmacokinetics.

Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA.

Bioconjug Chem. 2010 Dec 15;21(12):2153-63. doi: 10.1021/bc100261d. Epub 2010 Nov 5. Review.

PMID:
21053952
31.

A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human.

Poulin P, Ekins S, Theil FP.

Toxicol Appl Pharmacol. 2011 Jan 15;250(2):194-212. doi: 10.1016/j.taap.2010.10.014. Epub 2010 Oct 27.

PMID:
21034759
32.

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S.

MAbs. 2011 Jan-Feb;3(1):61-6. Epub 2011 Jan 1.

33.

Development and evaluation of a novel method for preclinical measurement of tissue vascular volume.

Boswell CA, Ferl GZ, Mundo EE, Schweiger MG, Marik J, Reich MP, Theil FP, Fielder PJ, Khawli LA.

Mol Pharm. 2010 Oct 4;7(5):1848-57. doi: 10.1021/mp100183k. Epub 2010 Aug 12.

PMID:
20704296
34.

Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling.

Wong H, Theil FP, Cui Y, Marsters JC Jr, Khojasteh SC, Vernillet L, La H, Song X, Wang H, Morinello EJ, Deng Y, Hop CE.

Drug Metab Dispos. 2010 Jul;38(7):1029-38. doi: 10.1124/dmd.110.032680. Epub 2010 Apr 20.

PMID:
20406853
35.

Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.

Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S.

Drug Metab Dispos. 2010 Apr;38(4):600-5. doi: 10.1124/dmd.109.031310. Epub 2010 Jan 13.

PMID:
20071453
36.
37.

Whole body physiologically-based pharmacokinetic models: their use in clinical drug development.

Edginton AN, Theil FP, Schmitt W, Willmann S.

Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1143-52. doi: 10.1517/17425255.4.9.1143 . Review.

PMID:
18721109
38.

[Trends in the pharmaceutical profile of intentional drug overdoses seen in the emergency room].

Staikowsky F, Theil F, Candella S.

Presse Med. 2005 Jul 2;34(12):842-6. French.

PMID:
16097205
39.

Change in profile of acute self drug-poisonings over a 10-year period.

Staikowsky F, Theil F, Mercadier P, Candella S, Benais JP.

Hum Exp Toxicol. 2004 Nov;23(11):507-11.

PMID:
15625775
40.

New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.

Angehrn P, Buchmann S, Funk C, Goetschi E, Gmuender H, Hebeisen P, Kostrewa D, Link H, Luebbers T, Masciadri R, Nielsen J, Reindl P, Ricklin F, Schmitt-Hoffmann A, Theil FP.

J Med Chem. 2004 Mar 11;47(6):1487-513.

PMID:
14998336
41.

Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.

Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T.

J Pharm Sci. 2003 Oct;92(10):1990-2007.

PMID:
14502539
42.

Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection.

Theil FP, Guentert TW, Haddad S, Poulin P.

Toxicol Lett. 2003 Feb 18;138(1-2):29-49. Review.

PMID:
12559691
43.

Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes.

Luttringer O, Theil FP, Lavé T, Wernli-Kuratli K, Guentert TW, de Saizieu A.

Biochem Pharmacol. 2002 Dec 1;64(11):1637-50.

PMID:
12429353
44.
46.

Prediction of human pharmacokinetics based on preclinical in vitro and in vivo data.

Lavé T, Luttringer O, Zuegge J, Schneider G, Coassolo P, Theil FP.

Ernst Schering Res Found Workshop. 2002;(37):81-104. Review. No abstract available.

PMID:
11975202
47.
48.
50.

Separation of Enantiomers by Extraction Based on Lipase-Catalyzed Enantiomer-Selective Fluorous-Phase Labeling.

Hungerhoff B, Sonnenschein H, Theil F.

Angew Chem Int Ed Engl. 2001 Jul 2;40(13):2492-2494. doi: 10.1002/1521-3773(20010702)40:13<2492::AID-ANIE2492>3.0.CO;2-8.

PMID:
29712284

Supplemental Content

Support Center